Last reviewed · How we verify

UV1 synthetic peptide vaccine and GM-CSF

Ultimovacs ASA · Phase 1 active Biologic

UV1 synthetic peptide vaccine and GM-CSF is a Biologic drug developed by Ultimovacs ASA. It is currently in Phase 1 development. Also known as: UV1, Leukine.

At a glance

Generic nameUV1 synthetic peptide vaccine and GM-CSF
Also known asUV1, Leukine
SponsorUltimovacs ASA
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about UV1 synthetic peptide vaccine and GM-CSF

What is UV1 synthetic peptide vaccine and GM-CSF?

UV1 synthetic peptide vaccine and GM-CSF is a Biologic drug developed by Ultimovacs ASA.

Who makes UV1 synthetic peptide vaccine and GM-CSF?

UV1 synthetic peptide vaccine and GM-CSF is developed by Ultimovacs ASA (see full Ultimovacs ASA pipeline at /company/ultimovacs-asa).

Is UV1 synthetic peptide vaccine and GM-CSF also known as anything else?

UV1 synthetic peptide vaccine and GM-CSF is also known as UV1, Leukine.

What development phase is UV1 synthetic peptide vaccine and GM-CSF in?

UV1 synthetic peptide vaccine and GM-CSF is in Phase 1.

Related